We investigated whether differences in IL-6 and IL-1␤ expression could be detected in monoclonal plasma cells from patients with MGUS or MM. Expression of IL-6 and IL-1␤ in bone marrow cells was determined using cell sorting to enrich for plasma cells followed by reverse transcriptase/polymerase chain reaction (RT/PCR). Nineteen patients (six MGUS, two primary amyloid (AL), 11 MM) were studied. IL-6 mRNA expression was detectable in the sorted CD38 ؉ /CD45 ؊ plasma cell populations from 0/6 MGUS, 0/2 AL and 5/11 MM patients. All five MM patients with autocrine IL-6 expression demonstrated an elevated plasma cell labeling index. IL-1␤ mRNA was detectable in the sorted CD38 ؉ /CD45 ؊ plasma cell populations from 1/6 MGUS, 0/2 AL and 10/11 MM patients. In situ hybridization (ISH) confirmed that the IL-1␤ producing cells were plasma cells. In conclusion, autocrine production of IL-6 parallels a high labeling index and aberrant expression of IL-1␤ correlates with the diagnosis of MM. Follow-up of IL-1␤-positive MGUS patients will determine whether aberrant expression of IL-1␤ will predict those MGUS patients that will eventually progress to MM.
Introduction
Multiple myeloma (MM) is a universally fatal B cell malignancy accounting for 1-2% of all cancer deaths. 1 It is critical to distinguish between patients with myeloma and individuals with monoclonal gammopathy of undetermined significance (MGUS) because MGUS patients may be safely observed without chemotherapy. 2 In a follow-up of 241 patients with MGUS, 59 patients (24.5%) went on to develop MM or a related plasma cell disorder. 3 Closer examination of those individuals who developed MM revealed that the majority of patients remained stable for an extended duration and then subsequently progressed to overt MM over a relatively short period of time. Of the 59 patients that progressed, 39 went on to develop multiple myeloma. Of the 32 patients who had serial serum studies performed, 25 remained stable for 1-25 years and then progressed to MM. Seven of these 25 progressed rapidly in less than 1 year after a stable period of 2-25 years (median 8). 3 Based on these clinical observations, we hypothesized that MGUS and MM are biologically distinct entities and that one or more genetic changes occur in MGUS cells that are responsible for the progression of MGUS to MM.
Previous studies suggest that interleukin-6 (IL-6) and interleukin-1␤ (IL-1␤) may be important in the pathogenesis of myeloma. [4] [5] [6] [7] Kishimoto and colleagues 4 have shown that interleukin-6 (IL-6) is a central growth factor for myeloma cells. Cozzolino et al 6 showed that plasma cell supernatants from patients with myeloma displayed strong osteoclast activating factor activity (OAF) that was inhibited by neutralizing anti-IL-1␤ antibodies. Clinically, the presence of lytic bone Correspondence: JA Lust; Fax: 507-266-4088 Received 7 April 1997; accepted 11 December 1997 lesions is a major feature used to distinguish MGUS from MM. 2 Since IL-1␤ has prominent OAF activity and IL-6 is a central growth factor for myeloma cells, then the aberrant expression of these cytokines may be important in the pathogenesis of MGUS to active myeloma.
In this study, we investigated whether differences in IL-6 and IL-1␤ expression could be detected in monoclonal plasma cells from patients with MGUS or myeloma. Since patients with MGUS exhibit low numbers of monoclonal plasma cells (Ͻ10% by definition), the levels of expression of IL-6 and IL-1␤ in bone marrow samples from patients with MGUS and active myeloma were studied using a combination of flow cytometry to enrich for monoclonal plasma cells followed by reverse transcriptase/polymerase chain reaction (RT/PCR). In addition, in situ hybridization was used to confirm morphologically that the cytokine producing cells were plasma cells.
Materials and methods

Patients
Nineteen patients with plasma cell proliferative disorders consisting of 11 patients with MM, six patients with MGUS and two patients with primary systemic amyloidosis (AL) were studied. Diagnoses were established using previously published criteria for MGUS and myeloma. 2 All patients with MM had greater than or equal to 10% bone marrow plasma cells. Eight of the eleven myeloma patients had bone lesions, seven with osteolytic lesions and one with osteoporosis only. Of the remaining three cases without bone lesions, two showed evidence of renal insufficiency and one was a case of smoldering multiple myeloma. 8 Both cases of primary amyloidosis had biopsy proven disease and no clinical evidence of active myeloma.
All samples used in this study were obtained from patients with informed consent according to Institutional Review Board guidelines.
Plasma cell labeling index
The percentages of bone marrow myeloma cells were determined by intracytoplasmic immunufluorescence using anti-or anti-light chain antibodies bound to fluorescein. The percentages of myeloma cells in the S-phase were determined using an anti-bromodeoxyuridine monoclonal antibody (BU-1) and a rhodamine-labeled goat antimouse immunoglobulin in a double fluorescence technique. The slides are read with a fluorescence microscope containing both fluorescein and rhodamine filters. This technique also allows identification of monoclonal plasma cells by both cell morphology and monoclonal cytoplasmic light chain staining. 
/CD45
− fraction contained greater than 95% plasma cells for all patients and this was confirmed morphologically. Subsequently, messenger RNA was isolated from 10 5 to 10 6 unsorted (U) and sorted (S) CD38 + /CD45 − cells. The cells were disrupted with high concentrations of guanidinium thiocyanate and mRNA was isolated using oligo-dT cellulose. First-strand cDNA was synthesized using sodium pyrophosphate, human placental ribonuclease inhibitor, buffer, and oligo-DT in a 20 l reaction mixture and incubated with AMV reverse transcriptase at 42°C for 90 min. Subsequently, 1 l of the cDNA reaction was added to a standard PCR mix with oligonucleotide primers for either IL-6, IL-1␤, IL-6R, or actin in a 50 l reaction.
IL-1␤
5Ј-ATGGCAGAAGTACCTAAGCTCGC-3Ј ACACAAATTGCATGGTGAAGTCAGTT
The IL-1␤ and IL-6 primers were designed to span the full length cDNA and, therefore, amplification is reflective of the mRNA expression and not residual contaminating DNA. The PCR was performed on a model 9600 thermal cycler according to the following cycling parameters: denaturation, 94°C for 30 s; annealing, 50°C for 30 s; and extension, 72°C for 1 min for 35 cycles. The PCR products were analyzed on a 2% agarose gel containing ethidium bromide. Fidelity of the amplified sequences was confirmed by fragment size comparison with a known control in all experiments and Southern blotting using oligonucleotide probes contained within the PCR fragments in selected cases.
In situ hybridization
A DNA 3Ј tailing kit (Boehringer Mannheim, Indianapolis, IN, USA) was used to tail 100 pg of an antisense oligonucleotide specific for a known portion of the human IL-1␤ gene with digoxigenin-11-dUTP according to the manufacturer's specifications. Bone marrow aspirates were centrifuged over a Ficoll-Hypaque density gradient to obtain the mononuclear layer. 1 × 10 5 cells were used to make cytospin slides. The cells were fixed in 4% paraformaldehyde, permeabilized in PBS with 0.3% Triton and prehybridized with hybridization solution (5 × SSC buffer, 1 × Denhardt's solution, 0.2 mg/ml yeast RNA, 0.02 M NaPO 4 ) at 37°C. The excess hybridization solution was wiped off and 25 l of probe (kappa, lambda or IL-1␤) was added to each slide. For each patient, a positive and negative control were done using commercially available FITC-labeled kappa and lambda probes (DAKO Corporation, Carpinteria, CA, USA). A blank slide with no probe at all was run on each patient to control for nonspecific staining. An anti-probe antibody was added (anti-Digoxigenin-AP for the IL-1␤ and blanks; anti-FITC-AP for the kappa and lambda). The slides were developed in NBT/BCIP, counterstained in hematoxylin and mounted using an aqueous mounting solution Crystalmount (Biomeda, Foster City, CA, USA). Slides were examined under a microscope and plasma cells scored as positive or negative for IL-1␤ mRNA.
Results
FACS sorting of monoclonal plasma cells and cytokine detection
Bone marrow samples from 19 patients with monoclonal plasma cell disorders were incubated with monoclonal antibodies against CD38 and CD45. Using flow cytometric methods CD38 Table 1 ). The identification of the IL-6 and IL-1␤ amplified sequences was confirmed by the expected size product on an ethidium bromide stained gel and by Southern blotting using oligonucleotide probes contained within the PCR fragments ( Figure 2 ). The pertinent clinical data and the results of mRNA expression for IL-6, IL-1␤, IL-6R and actin are detailed in Table 1 for all patients. The presence of message for IL-6R was a constant finding in both the unsorted and CD38 + /CD45 − populations from all patients ( Figure 2b and Table 1 ). We have previously reported the lower 245 bp band results from amplification of a cDNA that encodes for a soluble form of the IL-6R. 11, 12 IL-1␤ mRNA was detectable in normal peripheral blood leokocytes (Figure 2c ). Since bone marrows are often heavily contaminated with peripheral blood, the demonstration of IL-1␤ mRNA in the unsorted populations from all patients was anticipated. Therefore, in order to determine whether differences in IL-1␤ expression could be detected between patients with MGUS or MM, it was important to focus on the sorted CD38 + /CD45 − plasma cells. In contrast to IL-1, IL-6 mRNA was not detectable in normal peripheral blood leukocytes (Figure 2d) . Therefore, detection of IL-6 mRNA in both the sorted and unsorted bone marrow populations was informative. Specifically, detection of IL-6 expression in the sorted CD38
− plasma cells was con- sistent with a pattern of autocrine IL-6 production. In contrast, the presence of IL-6 mRNA in the unsorted bone marrow cells could be from autocrine and/or paracrine production.
Contrast in cytokine expression between patients with MGUS or MM
A comparison of the clinical diagnoses of MGUS, AL, or MM and IL-6 expression detected in the sorted CD38
− plasma cells is detailed in Table 2 . None of the six patients with MGUS or two patients with primary amyloid (AL) showed detectable IL-6 expression. In contrast, IL-6 expression was detectable in the sorted CD38 + /CD45 − plasma cells from 5/11 patients with MM. Since only some of the patients with MM were found to express IL-6 message, we investigated whether IL-6 expression correlated with any known clinical parameters. Interestingly, all five patients that exhibited autocrine IL-6 mRNA expression were found to have an elevated plasma cell labeling index (proliferation rate of the monoclonal plasma cells), LI у0.4% (Tables 2 and 3 ). Both the unsorted and sorted CD38
− populations from the three patients with a LI Ͻ0.4% failed to show detectable IL-6 expression by RT/PCR ( (Table 3 ). In summary, two different groups of patients were observed with an elevated labeling index (LI у0.4%). CD38
− cells from patient Nos 1, 2, 5, 10 and 11 all expressed IL-6 mRNA in an autocrine fashion, ie the IL-6 was produced by the monoclonal plasma cells. In contrast, patients No. 7 and No. 9 expressed IL-6 mRNA in a paracrine fashion, ie the IL-6 was produced by marrow stromal cells present in the unsorted bone marrow populations.
IL-1␤ mRNA was detectable in the CD38 + /CD45 − population from one patient with MGUS in the group of six MGUS patients studied, as shown in Table 4 . The two patients with AL, that demonstrated less than 10% of plasma cells, absence of bone lesions, and no evidence of active myeloma, were negative for IL-1␤ expression. In contrast, the CD38 + /CD45 − plasma cell fraction from 10 of 11 patients with myeloma showed detectable levels of IL-1␤ mRNA expression. Eight of the 11 myeloma patients had bone lesions, seven with osteolytic lesions, and one with osteoporosis only. Since IL-1␤ is a potent osteoclast activating factor, we hypothesized that CD38
− plasma cells from patients with bone lesions would express IL-1␤. Seven of eight patients with clinically significant bone disease were found to express IL-1␤. The one patient who did not express detectable IL-1␤ message may 12 with MGUS failed to demonstrate detectable IL-6 message in either the unsorted or sorted populations. The identity of the IL-1␤ and IL-6 amplified sequences was confirmed by the expected size when compared with a known control (C) and, in selected cases, by Southern blotting (S) using oligonucleotide probes contained within the amplified PCR fragments (c and d).
have been negative for technical reasons. Of significance, IL-1␤ mRNA was detectable in the CD38
− plasma cells from three patients with myeloma in which bone lesions were absent. Two of these individuals showed evidence of renal insufficiency and one was a case of smoldering myeloma. In summary, IL-1␤ mRNA is not detectable in plasma cells from the majority of patients with MGUS but is present in CD38 + /CD45 − cells from virtually all patients with MM and correlates best with the diagnosis of MM.
In situ hybridization for IL-1␤ expression
In situ hybridization was performed on bone marrow aspirates from a patient with MGUS and myeloma utilizing oligonucleotide probes for kappa and lambda light chains and IL-1␤. As shown in Figure 3 , sorted CD38
− plasma cells from a MGUS patient with a serum monoclonal protein of the kappa type displayed kappa mRNA expression by in situ hybridization identified by a prominent brown-black color in the cytoplasm of the monoclonal plasma cells. The sorted plasma cells from the same MGUS patient showed no detectable IL-1␤ expression by in situ hybridization. We have also determined that normal plasma cells do not express IL-1␤ by ISH (data not shown). In contrast, strong IL-1␤ expression was detectable in all the monoclonal plasma cells from the patient with myeloma (Figure 3a and b) by in situ hybridization. Most of the other non-plasma cells present in the marrow aspirate were negative for IL-1␤ expression except for macrophages and occasional granulocytes. The in situ hybridization results confirm that the IL-1␤ producing cells were plasma cells.
Discussion
The genetic changes that occur in the monoclonal plasma cells in the transition from MGUS to MM have not been clearly defined. Aberrant production of cytokines has been 
MM, multiple myeloma; SMM, smoldering myeloma; MGUS, monoclonal gammopathy of undetermined significance; AL, primary amyloidosis. Table 2 Comparison of diagnoses and IL-6 mRNA expression Diagnosis IL-6 mRNA detected in CD38
Table 3
Correlation of IL-6 mRNA expression and an elevated labeling index in patients with MM LI (%) IL-6 mRNA detected in Unsorted CD38 previously detected in monoclonal plasma cells from patients with MM and is likely to be important in the pathogenesis of plasmaproliferative disorders. [4] [5] [6] [7] [13] [14] [15] The studies in this report extend these earlier observations by investigating patients with MGUS using highly sensitive molecular techniques to detect cytokine expression. Furthermore, the above studies suggest a rational mechanism for the progression from MGUS to active myeloma.
The IL-1␤ and IL-6 expression studies from unsorted and sorted monoclonal plasma cells from patients with MGUS and myeloma in this report taken in conjunction with previously reported observations suggest that both autocrine and paracrine mechanisms of IL-6 production may be operational in the pathogenesis of myeloma. 4, [13] [14] [15] Our data demonstrate that monoclonal plasma cells from the majority of myeloma patients with active disease manifested by a high labeling index can express IL-6 mRNA in an autocrine fashion. Hata + /CD45 ϩ and produce IL-6 in an autocrine fashion. 16 Thus, myeloma cells can produce IL-6 in an autocrine fashion, however, it is likely that both autocrine and paracrine sources of IL-6 production play a role in the pathogenesis of myeloma. We found that sorted plasma cells from 10 of 11 myeloma patients expressed IL-1␤ message. Our results in myeloma patients are supported by several previous studies that have detected IL-1␤ at both the mRNA and protein levels. 6, 7, 17, 18 Two other studies failed to detect IL-1␤ production by enriched myeloma cells but may have failed to do so for technical reasons. 5, 19 Clearly, the majority of studies including this investigation confirm that monoclonal plasma cells from myeloma patients can produce IL-1␤.
Production of IL-1␤ by myeloma cells appears to be responsible for the paracrine generation of IL-6 by marrow stromal cells. Carter et al 7 have found that human myeloma cells are able to induce IL-6 production in marrow stromal cells. The stimulatory activity of the myeloma cells appears to be mediated through endogenously released IL-1 and antibodies to IL-1 completely abrogate the IL-6 production. 7 For example, sorted CD38
− myeloma cells from patients 7 and 9 demonstrated IL-1␤ production but no IL-6 production. However, the unsorted bone marrow cells from these patients did express IL-6 mRNA and the patients were both found to have a high labeling index. In these two cases, the IL-6 was most likely generated by marrow stromal cells present in the unsorted bone marrow specimens and not the monoclonal plasma cells. These results would be consistent with a paracrine IL-6 mechanism as the explanation for the proliferative activity of the myeloma cells. In summary, the IL-6 results suggest that both autocrine and paracrine mechanisms of IL-6 production play a role in the proliferation of myeloma cells that is manifested clinically by an elevated labeling index.
IL-1␤ expression appears to be able to differentiate between patients with MGUS or MM. IL-1␤ mRNA was not detectable in the plasma cells from most patients with MGUS but was expressed by plasma cells from virtually all patients with MM. Interestingly, one patient with MGUS was found to express detectable IL-1␤ mRNA. Follow-up of IL-1␤-positive MGUS patients such as this individual may determine whether aberrant expression of IL-1␤ is predictive of progression to active MM.
Could aberrant IL-1␤ production be contributing to the progression from MGUS to myeloma? IL-1 has potent osteoclast activating factor activity and can induce expression of the genes for IL-6 and adhesion proteins. 6, 7, 20 When tested in the fetal rat long bone assay, plasma cell supernates from patients with myeloma displayed strong OAF activity that could be neutralized by IL-1␤ inhibitors. 21 Hawley et al 22 introduced an IL-1 cDNA into an IL-6-dependent murine B cell line by retroviral-mediated gene transfer. After injection of these IL-1 producing B cells into syngeneic mice, these cells were shown to 'home' to the bone marrow and produce metastatic bone lesions. By comparison, intravenous injection of autonomously growing B cell lines generated in vitro by retroviral insertion of an IL-6 cDNA rarely resulted in bone marrow or bone metastases. 22 Subsequent work has shown that aberrant expression of IL-1 can alter adhesion molecules such as ICAM and CD44 on the surface of mouse plasmacytoma cells. 23 A similar mechanism may occur in human myeloma in which aberrant expression of IL-1␤ induces increased expression of adhesion molecules such as VLA-4, CD44, CD54, CD56, and other surface molecules on the monoclonal plasma cells. [24] [25] [26] [27] [28] The etiology of acquired IL-1␤ expression in myeloma is unknown. However, the IL-1␤ gene is highly inducible and its expression can be affected by many microbial and cellular products. 29 Recently, a role for Kaposi's sarcoma-associated herpesvirus (KSHV) in the pathogenesis of myeloma has been reported. 30 Although it has not been demonstrated for KSHV, Epstein-Barr virus (EBV), human immunodeficiency virus-1 (HIV-1) and respiratory syncytial virus (RSV) have been shown to up-regulate IL-1 expression either by directly interacting with genomic sequences or indirectly by altering levels of transcription factors involved in IL-1␤ expression. [31] [32] [33] If KSHV is involved in the pathogenesis of myeloma, it would not be unlikely that it could play a role either directly or indirectly in the aberrant expression of the IL-1␤ gene.
In summary, IL-1␤ has potent osteoclast activating factor activity, can increase the expression of adhesion molecules, and can induce paracrine IL-6 production. The increased production of adhesion molecules could explain why myeloma cells are found predominantly in the bone marrow. Subsequently, these 'fixed' monoclonal plasma cells could now stimulate osteoclasts through the production of IL-1␤ and paracrine generation of IL-6 resulting in osteolytic disease ( Figure  4 ). With continued progression of the myeloma, the monoclonal plasma cells may later acquire the ability to produce IL-6 in an autocrine fashion that will be manifested clinically by an elevated labeling index (Figure 4 ). In the future, continued follow-up of IL-1␤-positive and -negative MGUS patients should determine whether aberrant expression of IL-1␤ by monoclonal plasma cells is a critical genetic event in the progression of MGUS to myeloma.
